+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Allogeneic CAR Patent Landscape Analysis 2023

  • Report

  • 122 Pages
  • September 2023
  • Region: Global
  • Knowmade
  • ID: 5878957

How Can Allogeneic Car Revolutionize Car-T Cell Therapy ?

Report’s Key Features

  • PDF>120 slides
  • Excel database containing all patents analyzed in the report  (>400 patent families), including segmentations + hyperlink to updated online database (legal status, documents etc.)
  • IP trends, including time evolution of published patents, countries of patent filings and patents’ legal status
  • Ranking of main patent assignees
  • Key players’ IP position and relative strength of their patent portfolios
  • Analysis of collaborations and EP patent oppositions.
  • Segmentation: cells (T cells, NK, other), cells origin (PBMC from peripheral blood, iPSC, cord blood & placenta), gene editing tools (CRISPR, TALEN, ZFN, Meganuclease, other) and therapeutic area (hematological malignancies , solid tumor).

Allogeneic CAR, a faster and less expensive therapy than autologous CAR-T cells

The pipeline for cell and gene therapies has been increasing at a rapid rate as are clinical developments. According to the FDA, the number of investigational new drug applications for cell and gene therapies has more than doubled since 2017. To manage this influx, in March 2023, the Office of Therapeutic Products was established as the first super office at the FDA’s Center for Biologics Evaluation and Research. Chimeric antigen receptor (CAR) cell therapies are one of the major, and perhaps, best known, components of cell and gene therapies. CAR therapies, mainly to treat cancer, are immune cells engineered to express a chimeric receptor directed against tumor antigens. Currently, there are 2 main types of CAR therapies: autologous (patient-derived) and allogeneic (from healthy donor). Allogeneic CAR are produced from third-party healthy immune cells which confers many advantages. First, allogeneic CAR treatment enables the process to be done in 10 to 11 days versus a minimum of three weeks with autologous CAR therapy. This accelerated process eliminates the need for bridging therapy therefore allowing better results. Second, a high number of CAR immune cells can be produced from a single donor enabling an industrialized manufacturing processes. Moreover, CAR products can be standardized thanks to the production of batches of cryopreserved immune cells. This industrialization also leads to a reduction of manufacturing cost and ultimately reduces the price of treatments. However, allogeneic CAR can generate graft-versus-host disease, which is life-threatening. To overcome this major problem, companies and academics develop several approaches such as the use of various immune cells (e.g., NK, macrophage), the use of induced pluripotent stem cells or umbilical cord blood as source of immune cells or gene editing tools (e.g., CRISPR, TALEN). Currently, more than 100 clinical trials are in progress, but this number increases, reflecting the interest in this topic as well as the economic stakes for companies. However, to date, there is still no product on the European and United States markets, but some patent oppositions have already been initiated against key patents, and several newcomers, mainly American, are entering the allogeneic CAR field. In this evolving context, it is crucial to understand the intellectual property position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging technologies, and enable strategic decisions to strengthen market position.


The analysis of the time evolution of patent publications shows that interest in allogeneic CAR began in the late 2000s. However, in 2017, for the 1st time, two autologous CAR therapies have been approved by the FDA: KYMRIAH™ (tisagenlecleucel) from Novartis and YESCARTA™ (Axicabtagene Ciloleucel) from Kite Pharma, a Gilead company. These two therapies are CD19-directed genetically modified autologous T cell immunotherapies. This event allowed the CAR technology to fully develop and led to a significant increase in the number of patent families published since 2019 in allogeneic CAR area.

Analysis by segment

Allogeneic CAR have been investigated and the selected patent families labeled according to technologies to which they relate. This IP landscape features the following 4 types of segmentation: cells (T cells, NK, other), cells origin (PBMC from peripheral blood, iPSC, cord blood & placenta), gene editing tools (CRISPR, TALEN, ZFN, Meganuclease, other) and therapeutic areas (hematological malignancies , solid tumor).


EP oppositions

Currently, there is few EP oppositions which reflects the novelty of allogeneic CAR technology. Most of the proceedings are recent, having been filed in the past 5 years, and are still pending. For each opposed patent, the application date, assignee, opponent, opposition year, and results are detailed.

Identifying the companies that have recently emerged in the IP landscape

Among the players owning patent families related to allogeneic CAR, 31 newcomers were identified. These companies are either start-up firms (8) or established companies (23) developing their first technology in the field. Most IP newcomers are based in the U.S. and in Asia. It is possible that one of these innovative companies could become one of the next healthcare unicorns that the big corporations will be tempted to acquire.

IP profile of key players

This IP study includes a selection and description of main players. The patent portfolio analysis of main players includes a description of the assignee, patent portfolio description, time evolution of patent publication, main geographical coverage and live patents by technical segment. This IP profile overview is followed by the description of the technological content of their key patents and by a table with its clinical trials.


Moreover, the report also includes an Excel database with the 416 patent families analyzed in this study. This useful patent database allows for multi-criteria searches and includes patent publication numbers, hyperlinks to the original documents, priority dates, titles, abstracts, patent assignees, each patent’s current legal status and segmentation.

Table of Contents

  • CAR therapy
  • Scope of the report
  • Reading guide
  • Main patent assignees
  • Time evolution of patent publications
  • Ranking of most prolific patent applicants
  • Patenting activity of IP leading companies
  • Mapping of main current IP holders
  • Time evolution of main patent assignees
  • Startup companies
  • Established companies
  • IP leadership of patent applicants
  • IP prior art blocking potential of patent applicants
  • Key patents
  • Strength index of patent portfolios
  • Definition
  • Main assignees by technology
  • Cells
  • Cells origin
  • Gene editing tool
  • Therapeutic area
  • Overview, key patents & clinical trials of:
  • Adicet Bio
  • Allogene Therapeutics
  • Cellectis
  • CRISPR Therapeutics
  • Fate Therapeutics
  • Gracell
  • Precision Biosciences
  • Patent search, selection and analysis
  • Search strategy
  • Terminologies for patent analysis
  • Strength and blocking potential

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Adicet Bio
  • Allogene Therapeutics
  • Cellectis
  • CRISPR Therapeutics
  • Fate Therapeutics
  • Gracell
  • Precision Biosciences


For patent landscape analysis, the patent information is extracted from the FamPat worldwide patent database (Questel-ORBIT) which provides 100+ million patent documents from 95 worldwide patent offices.

The search strategy combines keyword-based searches with expert review and manual screening of the patents. Keywords are searched in the title, abstract, claims and description. Relevant IPC (International Patent Classification) and CPC (Cooperative Patent Classification) are also used for the patent search. The dataset of identified patents is manually cleaned of non-relevant patents. Citing and cited patents of selected relevant patents are also included in the search strategy. The search strategy (keywords and search equations) and the dataset of selected patents is provided in our reports.

The publisher's analysts (PhD team) combine their technical and patent expertise with powerful analytics tools and proprietary methodologies to deliver the most relevant patent analyses.